Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model

Leukemia

Volumn 21, Issue 7, 2007, Pages 1504-1513

  Hayun, M ^a   Okun, E ^a   Hayun, R ^a   Gafter, U ^b   Albeck, M ^a   Longo, D L ^c   Sredni, B ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; BRYOSTATIN 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL COUNT; CELL DIFFERENTIATION; CELL INFILTRATION; CELL STRAIN HL 60; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MACROPHAGE; MALE; MONOTHERAPY; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SPLEEN; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION;

EID: 34250732910     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404746     Document Type: Article

References (37)

1. Schiffer CA. Acute myeloid leukemia in adults. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL and Weichselbaum RR (eds). Cancer Medicine. Lea & Febiger: Philadelphia, PA, 1993, pp 1907-1933.
2. Rovera G, Santoli D, Damsky C. Human promyeloblastic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester. Proc Natl Acad Sci USA 1979; 76: 2779-2783.
3. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyeloblastic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980; 77: 2936-2940.
4. 3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 1981; 102 937-943.
5. Aihara H, Asaoka Y, Yoshida K, Nishizuka Y. Sustained activation of protein kinase C is essential to HL-60 cell differentiation to macrophage. Proc Natl Acad Sci USA 1991; 88: 11062-11066.
6. Mischak H, Pierce JH, Goodnight J, Kazanietz MG, Blumberg PM, Mushinski JF. Phorbol ester-induced myeloid differentiation is mediated by protein kinase C-alpha and -delta and not by protein kinase C-beta II, -epsilon, -zeta, and -eta. J Biol Chem 1993; 268: 20110-20115.
7. Huberman E, Callaham MF. Induction of terminal differentiation in human promyeloblastic leukemia cells by tumor-promoting agents. Proc Natl Acad Sci USA 1979; 76: 1293-1297.
8. Pettit GR, Herald CL, Doubek DL, Herald DL. Isolation and structure of Bryostatin-1. J Am Chem Soc 1982; 104: 6846-6848.
9. Steube KG, Grunicke D, Quentmeier H, Drexler HG. Different effects of the two protein kinase C activators Bryostatin-1 and TPA on growth and differentiation of human monocytic leukemia cell lines. Leuk Res 1993; 17: 897-901.
10. Hornung RL, Pearson JW, Beckwith M, Longo DL. Preclinical evaluation of Bryostatin-1 as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 1992; 52: 101-107.
11. Pettit GR. The Bryostatins. In: Herz W, Kirby GW, Steglich W and Tamm CH (eds). Progress in the Chemistry of Organic Natural Products. Springer-Verlag: New York, 1991, pp 154-195.
12. Mohammad RM, Wall NR, Dutcher JA, Al Katib AM. The addition of Bryostatin-1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 2000; 6: 4950-4956.
13. Berkow RL, Kraft AS. Bryostatin-1, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem Biophys Res Commun 1985; 131 1109-1116.
14. Kraft AS, William F, Pettit GR, Lilly MB. Varied differentiation responses of human leukemias to Bryostatin-1. Cancer Res 1989; 49: 1287-1293.
15. Kraft AS, Smith JB, Berkow RL. Bryostatin-1, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyeloblastic leukemia cells HL-60. Proc Natl Acad Sci USA 1986; 83: 1334-1338.
16. Smith JB, Smith L, Pettit GR. Bryostatins: Potent, new mitogens that mimic phorbol ester tumor promoters. Biochem Biophys Res Commun 1985; 132: 939-945.
17. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H et al. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 1993; 364: 249-252.
18. kip1 in PMA-induced differentiation of HL60 cells. FEBS Lett 2000; 472: 50-52.
19. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512.
20. Sredni B, Caspi RR, Klein A, Kalechman Y, Danziger Y, Ben Ya'akov M et al. A new immunomodulating compound (AS-101) with potential therapeutic application. Nature 1987; 330: 173-176.
21. Hayun M, Naor Y, Weil M, Albeck M, Peled A, Don J et al. The immunomodulator AS101 induces growth arrest and apoptosis in multiple myeloma: Association with the Akt/Survivin pathway. Biochem Pharmacol 2006; 72: 1423-1431.
22. Sredni B, Tichler T, Shani A, Catane R, Kaufman B, Strassmann G et al. Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101. J Natl Cancer Inst 1996; 88: 1276-1284.
23. Kalechman Y, Longo DL, Catane R, Shani A, Albeck M, Sredni B. Synergistic anti-tumoral effect of paclitaxel (Taxol)+AS101 in a murine model of B16 melanoma: Association with rasdependent signal-transduction pathways. Int J Cancer 2000; 86: 281-288.
24. Kalechman Y, Shani A, Dovrat S, Whisnant JK, Mettinger K, Albeck M et al. The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma. J Immunol 1996; 156: 1101-1109.
25. Kalechman Y, Albeck M, Oron M, Sobelman D, Gurwith M, Horwith G et al. Protective and restorative role of AS101 in combination with chemotherapy. Cancer Res 1991; 51: 1499-1503.
26. Sredni B, Kalechman Y, Shalit F, Albeck M. Synergism between AS101 and PMA in lymphokine production. Immunology 1990; 69: 110-116.
27. Sredni B, Kalechman Y, Albeck M, Gross O, Aurbach D, Sharon P et al. Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer Bryostatin-1. Immunology 1990; 70: 473-477.
28. Pluznik DH, Sachs L. The cloning of normal 'mast' cells in tissue culture. J Cell Physiol 1965; 66: 319-324.
29. Mayne M, Cheadle C, Soldan SS, Cermelli C, Yamano Y, Akhyani N et al. Gene expression profile of herpesvirus-infected T cells obtained using immunomicroarrays: Induction of proinflammatory mechanisms. J Virol 2001; 75: 11641-11650.
30. Tanaka TS, Jaradat SA, Lim MK, Kargul GJ, Wang X, Grahovac MJ et al. Genome-wide expression profiling of mid-gestation placenta and embryo using a 15,000 mouse developmental cDNA microarray. Proc Natl Acad Sci USA 2000; 97: 9127-9132.
31. 1 arrest. J Clin Invest 1992; 89: 954-960.
32. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 CDK-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
33. Carroll MP, May WS. Protein kinase C-mediated serine phosphorylation directly activates Raf-1 in murine hematopoietic cells. J Biol Chem 1994; 269: 1249-1256.
34. Schwaller J, Peters UR, Pabst T, Niklaus G, Macfarlane DE, Fey MF et al. Up-regulation of p21WAF1 expression in myeloid cells is activated by the protein kinase C pathway. Br J Cancer 1997; 76: 1554-1557.
35. Park MJ, Park IC, Lee HC, Woo SH, Lee JY, Hong YJ et al. Protein kinase C-alpha activation by phorbol ester induces secretion of gelatinase B/MMP-9 through ERK 1/2 pathway in capillary endothelial cells. Int J Oncol 2003; 22: 137-143.
36. Kharbanda S, Saleem A, Emoto Y, Stone R, Rapp U, Kufe D. Activation of Raf-1 and mitogen-activated protein kinases during monocytic differentiation of human myeloid leukemia cells. J Biol Chem 1994; 269: 872-878.
37. el Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.